A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat

Toxicology and Applied Pharmacology

Volumn 231, Issue 2, 2008, Pages 248-259

  Punt, Ans ^a,c   Freidig, Andreas P ^b   Delatour, Thierry ^c   Scholz, Gabriele ^c   Boersma, Marelle G ^a   Schilter, Benoît ^c   van Bladeren, Peter J ^a,c   Rietjens, Ivonne M C M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Bioactivation; Detoxification; Estragole; In vitro; PBPK; Rat

Indexed keywords

1' HYDROXYESTRAGOLE GLUCURONIDE; 1' SULFOOXYESTRAGOLE; BENZENE DERIVATIVE; CHAVICOL; ESTRAGOLE; GLUCURONIDE; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; BODY FAT; CONTROLLED STUDY; DETOXIFICATION; IN VITRO STUDY; KIDNEY; KINETICS; LIVER; LUNG; MALE; NONHUMAN; PARTITION COEFFICIENT; RAT; TISSUE PERFUSION; VENOUS BLOOD;

ALLYL COMPOUNDS; ANIMALS; ANISOLES; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONIDES; KIDNEY; LUNG; MALE; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SULFONES; TISSUE DISTRIBUTION;

RATTUS;

EID: 49549101796     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.04.011     Document Type: Article

References (38)

1. Agharahimi M.R., and LeBel N.A. Synthesis of (-)-monoterpenylmagnolol and magnolol. J. Org. Chem. 60 (1995) 1856-1863
2. Anthony A., Caldwell J., Hutt A.J., and Smith R.L. Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. Food Chem. Toxicol. 25 (1987) 799-806
3. Beierschmitt W.P., and Weiner M. Age-related changes in renal metabolism of acetaminophen in male fischer 344 rats. Age 9 (1986) 7-13
4. Bogaards J.J.P., Freidig A.P., and Van Bladeren P.J. Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. Chem. Biol. Interact. 138 (2001) 247-265
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
6. DeJongh J., Verhaar H.J.M., and Hermens J.L.M. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 72 (1997) 17-25
7. Drinkwater N.R., Miller E.C., Miller J.A., and Pitot H.C. Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1'-hydroxyestragole in the mouse and mutagenicity of 1'-acetoxyestragole in bacteria. J. Natl. Cancer Inst. 57 (1976) 1323-1331
8. EC-SCF. Opinion of the scientific committee on food on estragole (1-allyl-4-methyxybenzene) (2001). http://ec.europa.eu/food/fs/sc/scf/out104_en.pdf http://ec.europa.eu/food/fs/sc/scf/out104_en.pdf
9. Evans M.V., and Andersen M.E. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci. 54 (2000) 71-80
10. Evelo C.T.A., Oostendorp J.G.M., ten Berge W.F., and Borm P.J. Physiologically based toxicokinetic modeling of 1,3-butadiene lung metabolism in mice becomes more important at low doses. Environ. Health Perspect. 101 (1993) 496-502
11. Filser J.G., Faller T.H., Bhowmik S., Schuster A., Kessler W., Putz C., and Csanady G.A. First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice. Chem. Biol. Interact. 135-136 (2001) 249-265
12. Fisher M.B., Campanale K., Ackermann B.L., VandenBranden M., and Wrighton S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos. 28 (2000) 560-566
13. Garg A., and Balthasar J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn. 34 (2007) 687-709
14. Guenthner T.M., and Luo G. Investigation of the role of the 2',3'-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Toxicology 160 (2001) 47-58
15. Hissink A.M., Van Ommen B., Kruse J., and Van Bladeren P.J. A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. Toxicol. Appl. Pharmacol. 145 (1997) 301-310
16. Iyer L.V., Ho M.N., Shinn W.M., Bradford W.W., Tanga M.J., Nath S.S., and Green C.E. Glucuronidation of 1'-hydroxyestragole (1'-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. Toxicol. Sci. 73 (2003) 36-43
17. Koster H., Halsema I., Scholtens E., Knippers M., and Mulder G.J. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. Biochem. Pharmacol. 30 (1981) 2569-2575
18. Lin J.H., and Wong B.K. Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr. Drug Metab. 3 (2002) 623-646
19. Luo G., and Guenthner T.M. Covalent binding to DNA in vitro of 2',3'-oxides derived from allylbenzene analogs. Drug Metab. Dispos. 24 (1996) 1020-1027
20. Luo G., Qato M.K., and Guenthner T.M. Hydrolysis of the 2',3'-allylic epoxides of allylbenzene, estragole, eugenol, and safrole by both microsomal and cytosolic epoxide hydrolases. Drug Metab. Dispos. 20 (1992) 440-445
21. Lupfert C., and Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem. Biodivers. 2 (2005) 1462-1486
22. Medinsky M.A., Leavens T.L., Csanady G.A., Gargas M.L., and Bond J.A. In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. Carcinogenesis 15 (1994) 1329-1340
23. Miller E.C., Swanson A.B., Phillips D.H., Fletcher T.L., Liem A., and Miller J.A. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 43 (1983) 1124-1134
24. Paraskar A.S., and Sudalai A. Enantioselective synthesis of (-)-cytoxazone and (+)-epi-cytoxazone, novel cytokine modulators via Sharpless asymmetric epoxidation and -proline catalyzed Mannich reaction. Tetrahedron 62 (2006) 5756-5762
25. Passreiter C.M., Wilson J., Andersen R., and Isman M.B. Metabolism of thymol and trans-anethole in larvae of Spodoptera litura and Trichoplusia ni (Lepidoptera: Noctuidae). J. Agric. Food Chem. 52 (2004) 2549-2551
26. Phillips D.H., Miller J.A., Miller E.C., and Adams B. Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen 1'-hydroxyestragole. Cancer Res. 41 (1981) 176-186
27. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. Carcinogenesis 5 (1984) 1623-1628
28. 2-(trans-Isoestragol-3'-yl)-2'-deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1'-hydroxyestragole. Chem. Res. Toxicol. 20 (2007) 991-998
29. Quick D.J., and Shuler M.L. Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol. Prog. 15 (1999) 540-555
30. Ramsey J.C., and Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73 (1984) 159-175
31. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis 5 (1984) 1613-1622
32. Reitz R.H., Gargas M.L., Mendrala A.L., and Schumann A.M. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans. Toxicol. Appl. Pharmacol. 136 (1996) 289-306
33. Smith R.L., Adams T.B., Doull J., Feron V.J., Goodman J.I., Marnett L.J., Portoghese P.S., Waddell W.J., Wagner B.M., Rogers A.E., Caldwell J., and Sipes I.G. Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. Food Chem. Toxicol. 40 (2002) 851-870
34. Solheim E., and Scheline R. Metabolism of alkenebenzene derivatives in the rat I. p-Methoxyallylbenzene (estragole) and p-Methoxypropenylbenzene (Anethole). Xenobiotica 3 (1973) 493-510
35. Tardif R., Droz P.O., Charest-Tardif G., Pierrehumbert G., and Truchon G. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. Toxicol. Lett. 134 (2002) 155-163
36. Wiseman R.W., Fennell T.R., Miller J.A., and Miller E.C. Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1'-hydroxysafrole and 1'-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. Cancer Res. 45 (1985) 3096-3105
37. 1mice. Cancer Res. 47 (1987) 2275-2283
38. Yoon M., Madden M.C., and Barton H.A. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics. J. Toxicol. Environ. Health A 70 (2007) 1527-1541